A Study of 0.03% Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular Hypertension

This study will evaluate 0.03% bimatoprost in the treatment of primary open angle glaucoma and ocular hypertension.

Inclusion Criteria:

• Diagnosis of open-angle glaucoma or ocular hypertension
• No use of Lumigan® in the past 3 months

Exclusion Criteria:

• Received laser therapy, glaucoma surgery, cataract surgery, or other ocular surgery within the past 3 months